TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.

Canada Pension Plan Investment Board purchased a new position in shares of Biogen Inc. (NASDAQ: BIIB

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?

FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market an

Bank of Nova Scotia purchased a new stake in Biogen Inc. (NASDAQ: BIIB) during the second quarter, a

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises th

Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB), announced today that once weekly lecanemab-irmb subcu

LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for

LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for

Allworth Financial LP acquired a new stake in Biogen Inc. (NASDAQ: BIIB) in the undefined quarter, a

Shares of Biogen Inc. (NASDAQ: BIIB - Get Free Report) have received an average recommendation of "M

BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS

BlackRock Inc. bought a new stake in Biogen Inc. (NASDAQ: BIIB) during the second quarter, according

Wolfe Research analyst Alexandria Hammond upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outp

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the c

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price t

Citigroup analyst Geoff Meacham maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the pric

Amundi increased its stake in Biogen Inc. (NASDAQ: BIIB) by 38.2% in the first quarter, according to

HC Wainwright & Co. analyst Andrew S. Fein maintains Biogen (NASDAQ:BIIB) with a Buy and rais

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and ra

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers th

Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises th

TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price targe

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price ta

It handily beat analyst estimates on both the top and bottom lines. Investors didn't even mind a cut

Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript

Biogen Inc. (NASDAQ:BIIB) stock is trading higher on Wednesday after the company reported second-qua

Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pi

Pre-market futures are flat-to-down ahead of today's open, with overseas turbulence in the memory ch

Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and su

A quarter-points rate hike has been bandied about as a possibility today.

Biogen Inc. is upgraded to 'Buy' as strategic acquisitions and pipeline progress offset multiple scl

Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the qua

Biogen NASDAQ: BIIB reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year ea

Biogen (NASDAQ:BIIB) raises FY2026 Adj EPS guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 an

Barclays analyst Emily Field maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the pr

Guggenheim analyst Brad Canino maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price tar

B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers

Biogen stock drops 9% as Phase 2 diranersen data raises analyst questions, despite Phase 3 plans and

Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that results from the real-world Lecan

Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen,

TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (NASDA

Top Wall Street analysts changed their outlook on top names. Upgrade on NIO, COF, KEYS, BIIB, and AX

Truist Securities analyst Srikripa Devarakonda upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lo

A July filing shows that Representative Maria Elvira Salazar reported a purchase in Brookfield Renew

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises th

Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will

Analyst raised sales estimates for Spinraza HD due to positive uptake. Biogen makes strides in key p

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clin